v3.26.1
Other (Income)/Deductions—Net - Schedule of Other (Income)/Deductions—Net (Detail) - USD ($)
$ in Millions
 3 Months Ended
Mar. 29, 2026
Mar. 30, 2025
Other Income and Expenses [Abstract]    
Interest income $ (115) $ (143)
Interest expense 668 654
Net interest expense 554 511
Net (gains)/losses recognized during the period on equity securities [1] 9 370
Net periodic benefit costs/(credits) other than service costs (72) (158)
Certain legal matters, net [2] 191 142
Certain asset impairments [3] 0 224
Changes in fair value of contingent consideration liabilities [4] 295 8
Other, net (116) (144)
Other (income)/deductions––net $ 861 $ 953
[1] Reported in Other (income)/deductions––net. See Note 4.
[2] The amount for the first quarter of 2026 primarily includes certain product liability expenses related to products discontinued and/or divested by Pfizer. The amount for the first quarter of 2025 included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.
[3] The amount for the first quarter of 2025 primarily represented an intangible asset impairment charge associated with our Biopharma segment of $210 million for a Phase 2 indefinite-lived out-licensed asset that was discontinued by our out-licensing partner.
[4] See Notes 1D and 16D in our 2025 Form 10-K and Note 7A.